Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity

Michael H. Davidson,Andrew Hsieh,John J.P. Kastelein
DOI: https://doi.org/10.1097/mol.0000000000000955
IF: 4.616
2024-10-19
Current Opinion in Lipidology
Abstract:Cholesteryl ester transfer protein (CETP) is a hydrophobic glycoprotein that is a member of the lipid transfer protein family [1–3] . It facilitates the bidirectional exchange of cholesteryl esters and triglycerides among lipoprotein particles leading to a net mass transfer of cholesteryl esters from high-density lipoprotein (HDL) to low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) particles. In addition, triglycerides are transferred in the opposite direction from LDL and VLDL to HDL [1,2] . Interest in CETP inhibition as a therapeutic target began with the discovery in observational studies that some CETP gene polymorphisms were associated with reduced coronary heart disease (CHD) incidence and CHD mortality, although these results have not been entirely consistent [2,4–6] . However, taking all evidence into consideration, observational studies, Mendelian randomization (MR) analyses, and randomized clinical trials of pharmaceutical agents indicate that CETP inhibition confers cardiovascular benefit and reduces risk of atherosclerotic cardiovascular disease (ASCVD) [6,7,8▪▪,9▪▪] . Additionally, emerging evidence suggests that CETP inhibition may promote longevity [10▪,11] , presumably by lowering the risk of several conditions associated with aging such as new-onset type 2 diabetes mellitus (T2D), dementia, chronic kidney disease (CKD), and age-related macular degeneration (AMD), as well as promoting survival in septicemia [12▪▪,13▪▪] .
biochemistry & molecular biology,endocrinology & metabolism,peripheral vascular disease
What problem does this paper attempt to address?